VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
RGAReinsurance Group of America, Incorporated
$215.28$14.1B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksRGAFinancials

Reinsurance Group of America, Incorporated (RGA) Financials

30Y historyFree accessUpdated daily

Revenue growth accelerated to 22.4% in 2026Q1, supported by a combined ratio improvement to 93.2% as mortality experience normalizes from 2024 peaks.

RGA Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Revenue24.59B22.79B22.04B18.39B15.88B16.06B14.58B14.2B12.88B12.52B11.52B10.42B10.9B10.32B9.84B8.83B8.26B7.07B5.68B5.72B5.19B4.58B4.04B3.2B2.38B1.97B1.73B1.61B1.34B978.2M771.2M
Revenue Growth %17.29%3.39%19.85%15.82%-1.13%10.13%2.71%10.27%2.88%8.63%10.59%-4.46%5.68%4.85%11.45%6.87%16.91%24.39%-0.65%10.1%13.28%13.51%26.02%34.55%21.02%14.06%7.38%19.53%37.45%26.84%15.43%
Medical Costs & Claims19.59B17B19.55B16.06B14.31B14.21B13.04B12.1B11.07B10.49B9.67B8.95B9.25B9.08B8.35B7.53B6.99B6.1B5.05B4.88B4.2B3.82B3.27B2.57B1.93B1.68B1.35B1.29B986.37M788.16M678.54M
Medical Cost Ratio %79.67%74.6%88.71%87.33%90.11%88.46%89.41%85.2%85.95%83.8%83.92%85.94%84.82%88.01%84.87%85.3%84.66%86.34%88.94%85.3%80.96%83.26%80.95%80.08%81.06%85.4%78.06%79.99%73.36%80.57%87.99%
Gross Profit5B5.79B2.49B2.33B1.57B1.85B1.54B2.1B1.81B2.03B1.85B1.46B1.66B1.24B1.49B1.3B1.27B965.33M628.19M840.47M989M767.5M769.35M638.4M451.04M287.3M378.65M321.66M358.12M190.04M92.66M
Gross Margin %20.33%25.4%11.29%12.67%9.89%11.54%10.59%14.8%14.05%16.2%16.08%14.06%15.18%11.99%15.13%14.7%15.34%13.66%11.06%14.7%19.04%16.74%19.05%19.92%18.94%14.6%21.94%20.01%26.64%19.43%12.01%
Gross Profit Growth %-132.64%6.74%48.38%-15.26%20.08%-26.51%16.14%-10.8%9.45%26.53%-11.52%33.83%-16.92%14.68%2.44%31.25%53.67%-25.26%-15.02%28.86%-0.24%20.51%41.54%56.99%-24.13%17.72%-10.18%88.45%105.1%-83.74%
Operating Expenses3.39B4.25B1.51B1.17B853M469M991M969M963M885M808.96M719.55M646.56M601.47M569.3M534.37M460.82M372.99M347.8M365.55M537.61M411.16M400.16M366.79M257.04M221.1M203.65M228.59M220.07M-632.26M-554.25M
OpEx / Revenue %13.78%18.64%6.84%6.37%5.37%2.92%6.8%6.82%7.48%7.07%7.02%6.91%5.93%5.83%5.79%6.05%5.58%5.28%6.12%6.39%10.35%8.97%9.91%11.44%10.79%11.23%11.8%14.22%16.37%-64.64%-71.87%
Depreciation & Amortization043M46M41M38M43M49M49M45M53M26.85M31.1M15.31M000000-75.66M-53.34M-40.29M-32.58M-40.23M-35.9M-38.98M-35.88M-26.7M1.48M-14.1M-7.8M
Combined Ratio %93.45%93.24%95.55%93.69%95.48%91.38%96.21%92.03%93.43%90.87%90.94%92.85%90.75%93.84%90.66%91.35%90.24%91.62%95.06%91.69%91.31%92.23%90.86%91.53%91.86%96.64%89.86%94.21%89.73%15.94%16.12%
Operating Income1.61B1.54B980M1.16B718M1.39B553M1.13B846M1.14B1.04B744.79M1.01B635.25M919.22M763.57M806.18M592.35M280.39M474.92M451.39M356.35M369.19M271.61M194M66.2M175M93.07M138.05M822.3M646.9M
Operating Margin %6.55%6.76%4.45%6.31%4.52%8.62%3.79%7.97%6.57%9.13%9.06%7.15%9.25%6.16%9.34%8.65%9.76%8.38%4.94%8.31%8.69%7.77%9.14%8.47%8.14%3.36%10.14%5.79%10.27%84.06%83.88%
Operating Income Growth %-57.14%-15.52%61.56%-48.16%150.45%-51.15%33.81%-25.98%9.49%40.17%-26.15%58.76%-30.89%20.38%-5.29%36.1%111.26%-40.96%5.21%26.67%-3.48%35.93%40.01%193.05%-62.17%88.03%-32.58%-83.21%27.11%13.49%
EBITDA2B1.58B1.03B1.2B756M1.43B602M1.18B891M1.2B1.07B775.9M1.02B759.56M1.02B866.21M897.18M662.28M356.55M399.26M398.04M316.06M336.61M231.38M158.1M27.21M139.12M66.37M139.53M808.2M639.1M
EBITDA Margin %8.12%6.95%4.65%6.53%4.76%8.89%4.13%8.32%6.92%9.56%9.29%7.45%9.39%7.36%10.41%9.81%10.86%9.37%6.28%6.98%7.66%6.89%8.33%7.22%6.64%1.38%8.06%4.13%10.38%82.62%82.87%
Interest Expense386M366M304M257M191M139M170M173M147M146M137.62M142.86M96.7M124.31M105.35M102.64M91M69.94M76.16M76.91M306.8M249.8M237.37M216.49M35.52M129.8M122.4M164.14M162.05M7.8M6.2M
Non-Operating Income-386M-366M-304M-257M-191M-139M-170M-173M-147M-146M-137.62M-142.86M-96.7M-124.31M-105.35M-102.64M-91M-69.94M-76.16M-76.91M-306.8M-249.8M-237.37M-216.49M-35.52M-129.8M-122.4M-164.14M-162.05M814.5M640.7M
Pretax Income1.61B1.54B980M1.16B718M1.39B553M1.13B846M1.14B1.04B744.79M1.01B635.25M919.22M763.57M806.18M592.35M280.39M474.92M451.39M356.35M369.19M271.61M194M66.2M175M93.07M138.05M113M90.9M
Pretax Margin %6.55%6.76%4.45%6.31%4.52%8.62%3.79%7.97%6.57%9.13%9.06%7.15%9.25%6.16%9.34%8.65%9.76%8.38%4.94%8.31%8.69%7.77%9.14%8.47%8.14%3.36%10.14%5.79%10.27%11.55%11.79%
Income Tax380M351M256M251M197M215M138M262M130M-679M342.5M242.63M324.49M216.42M287.33M217.53M270.44M185.26M92.58M166.65M158.13M120.74M123.89M93.29M65.52M26.25M69.27M39.06M49.05M40.4M33.1M
Effective Tax Rate %23.57%22.79%26.12%21.64%27.44%15.52%24.95%23.14%15.37%-59.41%32.81%32.58%32.17%34.07%31.26%28.49%33.55%31.28%33.02%35.09%35.03%33.88%33.56%34.35%33.77%39.65%39.58%41.97%35.53%35.75%36.41%
Net Income1.23B1.18B717M902M517M1.17B415M870M716M1.82B701.44M502.17M684.05M418.84M631.89M546.04M535.74M407.09M176.8M293.83M288.21M224.18M221.89M173.14M122.81M33M77.7M40.86M62.08M54.6M55.1M
Net Margin %4.98%5.19%3.25%4.9%3.26%7.28%2.85%6.13%5.56%14.56%6.09%4.82%6.27%4.06%6.42%6.18%6.48%5.76%3.11%5.14%5.55%4.89%5.49%5.4%5.16%1.68%4.5%2.54%4.62%5.58%7.14%
Net Income Growth %54.6%64.85%-20.51%74.47%-55.81%181.93%-52.3%21.51%-60.7%159.75%39.68%-26.59%63.32%-33.72%15.72%1.92%31.6%130.26%-39.83%1.95%28.56%1.03%28.16%40.99%272.14%-57.53%90.17%-34.19%13.7%-0.91%16.49%
EPS (Diluted)18.3717.6910.7313.447.649.046.3113.6211.0027.7110.797.469.785.788.528.097.695.552.844.574.573.523.523.362.470.661.560.881.461.421.44
EPS Growth %55.7%64.86%-20.16%75.92%-15.49%43.26%-53.67%23.82%-60.3%156.81%44.64%-23.72%69.2%-32.16%5.32%5.2%38.56%95.42%-37.86%0%29.83%0%4.76%36.03%274.24%-57.69%77.27%-39.73%2.82%-1.39%15.2%
EPS (Basic)-17.9410.9013.607.739.106.3513.8811.2528.2810.917.559.885.828.578.157.695.592.844.754.713.583.563.372.490.671.570.891.501.441.45
Diluted Shares Outstanding66.73M66.73M66.9M67.1M67.7M68.3M65.8M63.88M65.09M65.75M64.99M67.29M69.96M72.46M74.15M74.11M74.69M73.33M65.27M64.23M63.06M63.69M63.04M51.53M49.72M50M49.81M46.25M42.56M38.45M38.26M

Key Metrics

Growth RegimeExpanding
ProfitabilityModerate
Balance SheetHealthy
Cash FlowRobust
Top Statement Risk

Mortality and morbidity volatility

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Premium Growth Sustains Upward Momentum

As indicated by the most recent quarterly data, RGA achieved a 22.4% revenue growth rate in 2026Q1, signaling a robust expansion in premium volume that contrasts with the more volatile growth patterns observed throughout the 2024 fiscal year, where quarterly growth fluctuated significantly between 5.5% and 50.2%.

The recent acceleration in top-line growth suggests that RGA is successfully capturing market share in its core life and health reinsurance segments. Investors should monitor whether this expansion is driven by sustainable long-term treaty acquisitions or if it reflects a temporary surge in capital-intensive financial solutions business.

Underwriting Profitability Shows Structural Improvement

Based on reported financial statements, the combined ratio improved to 93.2% in 2026Q1, reflecting a meaningful recovery from the elevated loss ratios observed in 2024, where the combined ratio peaked at 96.7% during the 2023Q4 period, suggesting a normalization of mortality experience across the portfolio.

The reduction in the loss ratio from the 90% range seen in mid-2024 to 71.4% in the most recent quarter implies that the company is effectively managing its mortality and morbidity risk. This trend warrants further investigation to determine if the improvement is sustainable or merely a result of favorable seasonal claim patterns.

Post-Pandemic Normalization Drives Earnings Recovery

According to the provided income statement data, RGA's operating income reached $441.0 million in 2026Q1, marking a significant inflection point from the depressed earnings levels of 2024, when operating income frequently struggled to exceed the $250 million threshold due to persistent mortality headwinds and elevated claim costs.

This earnings recovery appears to validate the thesis that the company has moved past the peak mortality volatility associated with the 2020-2022 period. The shift suggests that the underlying actuarial assumptions are now better aligned with current mortality trends, potentially providing a more stable foundation for future profitability.

Longevity Risk and Capital Sensitivity

While recent performance appears strong, the company's increasing exposure to the Pension Risk Transfer market, as noted in industry filings, may introduce long-term longevity risks that are not fully captured in current quarterly earnings, potentially masking future liabilities related to extended life expectancy trends.

Investors should remain cautious regarding the long-term impact of these asset-intensive transactions on the company's capital requirements. The reliance on these large, lumpy deals may create future earnings volatility if interest rate assumptions or longevity projections deviate from the company's current internal models.

RGA — Frequently Asked Questions

Quick answers to the most common questions about buying RGA stock.

What was Reinsurance Group of America, Incorporated's (RGA) revenue in 2025?

For fiscal year 2025, Reinsurance Group of America, Incorporated (RGA) reported total revenue of $22.79B. This represents a 2855.3% increase compared to $771.2M in 1996.

Is Reinsurance Group of America, Incorporated (RGA) profitable?

Reinsurance Group of America, Incorporated (RGA) is profitable, generating $1.18B in net income for the fiscal year ending 2025 with a net profit margin of 5.2%.

What is Reinsurance Group of America, Incorporated's operating profit margin?

Reinsurance Group of America, Incorporated (RGA) reported an operating income of $1.54B, resulting in an operating profit margin of 6.8%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Reinsurance Group of America, Incorporated's gross profit and gross margin?

Reinsurance Group of America, Incorporated (RGA) generated $5.79B in gross profit for the year, representing a gross profit margin of 25.4%. This demonstrates the company's core pricing power and production efficiency.